In:
Clinical Nuclear Medicine, Ovid Technologies (Wolters Kluwer Health), Vol. 48, No. 10 ( 2023-10), p. 861-868
Abstract:
This head-to-head comparison study was designed to investigate the radiotracer uptake and clinical feasibility of using 68 Ga-LNC1007, to detect the primary and metastatic lesions in patients with various types of cancer, and to compare the results with those of 2- 18 F-FDG PET/CT and 68 Ga-FAPI-02 PET/CT. Patients and Methods Sixty-one patients with 10 different kinds of cancers were enrolled in this study. Among them, 50 patients underwent paired 68 Ga-LNC1007 and 2- 18 F-FDG PET/CT, and the other 11 patients underwent paired 68 Ga-LNC1007 and 68 Ga-FAPI-02 PET/CT. The final diagnosis was based on histopathological results and diagnostic radiology. Immunohistochemistry for FAP and integrin α v β 3 was performed in 24 primary tumors. Results 68 Ga-LNC1007 PET/CT detected all 55 primary tumors, whereas 2- 18 F-FDG PET/CT was visually positive for 45 primary tumors ( P = 0.002). Furthermore, subgroup analysis showed that 68 Ga-LNC1007 PET/CT was superior to 2- 18 F-FDG PET/CT in diagnosing renal cell carcinomas and hepatocellular carcinomas. For metastatic tumors, 68 Ga-LNC1007 PET/CT revealed more PET-positive lesions and higher SUV max for skeletal metastases and peritoneal metastases compared with 2- 18 F-FDG. The SUV max and tumor-to-background ratio of primary tumors on 68 Ga-LNC1007 PET/CT were much higher than those on 68 Ga-FAPI-02 PET/CT, the same was also observed for metastatic tumors. Immunohistochemical results showed that the SUV mean quantified from 68 Ga-LNC1007 PET was correlated with FAP expression level ( r = 0.564, P = 0.005). Conclusions 68 Ga-LNC1007 is a promising new diagnostic PET tracer for imaging of various kinds of malignant lesions. It may be a better alternative to 2- 18 F-FDG for diagnosing renal cell carcinoma, hepatocellular carcinoma, skeletal metastases, and peritoneal metastases.
Type of Medium:
Online Resource
ISSN:
1536-0229
,
0363-9762
DOI:
10.1097/RLU.0000000000004820
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2023
detail.hit.zdb_id:
2045053-9
detail.hit.zdb_id:
197628-X
